Cargando…

The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System

CONTEXT: Adrenal insufficiency (AI) is a life-threatening condition complicating heterogeneous disorders across various disciplines, with challenging diagnosis and a notable drug-induced component. OBJECTIVE: This work aimed to describe the spectrum of drug-induced AI through adverse drug event repo...

Descripción completa

Detalles Bibliográficos
Autores principales: Raschi, Emanuel, Fusaroli, Michele, Massari, Francesco, Mollica, Veronica, Repaci, Andrea, Ardizzoni, Andrea, Poluzzi, Elisabetta, Pagotto, Uberto, Di Dalmazi, Guido
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282361/
https://www.ncbi.nlm.nih.gov/pubmed/35704533
http://dx.doi.org/10.1210/clinem/dgac359
_version_ 1784747086943617024
author Raschi, Emanuel
Fusaroli, Michele
Massari, Francesco
Mollica, Veronica
Repaci, Andrea
Ardizzoni, Andrea
Poluzzi, Elisabetta
Pagotto, Uberto
Di Dalmazi, Guido
author_facet Raschi, Emanuel
Fusaroli, Michele
Massari, Francesco
Mollica, Veronica
Repaci, Andrea
Ardizzoni, Andrea
Poluzzi, Elisabetta
Pagotto, Uberto
Di Dalmazi, Guido
author_sort Raschi, Emanuel
collection PubMed
description CONTEXT: Adrenal insufficiency (AI) is a life-threatening condition complicating heterogeneous disorders across various disciplines, with challenging diagnosis and a notable drug-induced component. OBJECTIVE: This work aimed to describe the spectrum of drug-induced AI through adverse drug event reports received by the US Food and Drug Administration (FDA). METHODS: A retrospective disproportionality analysis reporting trends of drug-induced AI was conducted on the FDA Adverse Event Reporting System (FAERS) (> 15 000 000 reports since 2004). AE reports were extracted from FAERS over the past 2 decades. Interventions included cases containing any of the preferred terms in the Medical Dictionary for Regulatory Activities describing AI, and signals of disproportionate reporting for drugs recorded in 10 or more cases as primary suspect. RESULTS: We identified 8496 cases of AI: 97.5% serious, 41.1% requiring hospitalization. AI showed an exponential increase throughout the years, with 5282 (62.2%) cases in 2015 to 2020. We identified 56 compounds associated with substantial disproportionality: glucocorticoids (N = 1971), monoclonal antibodies (N = 1644, of which N = 1330 were associated with immune checkpoint inhibitors—ICIs), hormone therapy (N = 291), anti-infectives (N = 252), drugs for hypercortisolism or adrenocortical cancer diagnosis/treatment (N = 169), and protein kinase inhibitors (N = 138). Cases of AI by glucocorticoids were stable in each 5-year period (22%-27%), whereas those by monoclonal antibodies, largely ICIs, peaked from 13% in 2010 to 2015 to 33% in 2015 to 2020. CONCLUSION: We provide a comprehensive insight into the evolution of drug-induced AI, highlighting the heterogeneous spectrum of culprit drug classes and the emerging increased reporting of ICIs. We claim for the urgent identification of predictive factors for drug-induced AI, and the establishment of screening and educational protocols for patients and caregivers.
format Online
Article
Text
id pubmed-9282361
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92823612022-07-18 The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System Raschi, Emanuel Fusaroli, Michele Massari, Francesco Mollica, Veronica Repaci, Andrea Ardizzoni, Andrea Poluzzi, Elisabetta Pagotto, Uberto Di Dalmazi, Guido J Clin Endocrinol Metab Online Only Articles CONTEXT: Adrenal insufficiency (AI) is a life-threatening condition complicating heterogeneous disorders across various disciplines, with challenging diagnosis and a notable drug-induced component. OBJECTIVE: This work aimed to describe the spectrum of drug-induced AI through adverse drug event reports received by the US Food and Drug Administration (FDA). METHODS: A retrospective disproportionality analysis reporting trends of drug-induced AI was conducted on the FDA Adverse Event Reporting System (FAERS) (> 15 000 000 reports since 2004). AE reports were extracted from FAERS over the past 2 decades. Interventions included cases containing any of the preferred terms in the Medical Dictionary for Regulatory Activities describing AI, and signals of disproportionate reporting for drugs recorded in 10 or more cases as primary suspect. RESULTS: We identified 8496 cases of AI: 97.5% serious, 41.1% requiring hospitalization. AI showed an exponential increase throughout the years, with 5282 (62.2%) cases in 2015 to 2020. We identified 56 compounds associated with substantial disproportionality: glucocorticoids (N = 1971), monoclonal antibodies (N = 1644, of which N = 1330 were associated with immune checkpoint inhibitors—ICIs), hormone therapy (N = 291), anti-infectives (N = 252), drugs for hypercortisolism or adrenocortical cancer diagnosis/treatment (N = 169), and protein kinase inhibitors (N = 138). Cases of AI by glucocorticoids were stable in each 5-year period (22%-27%), whereas those by monoclonal antibodies, largely ICIs, peaked from 13% in 2010 to 2015 to 33% in 2015 to 2020. CONCLUSION: We provide a comprehensive insight into the evolution of drug-induced AI, highlighting the heterogeneous spectrum of culprit drug classes and the emerging increased reporting of ICIs. We claim for the urgent identification of predictive factors for drug-induced AI, and the establishment of screening and educational protocols for patients and caregivers. Oxford University Press 2022-06-15 /pmc/articles/PMC9282361/ /pubmed/35704533 http://dx.doi.org/10.1210/clinem/dgac359 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Online Only Articles
Raschi, Emanuel
Fusaroli, Michele
Massari, Francesco
Mollica, Veronica
Repaci, Andrea
Ardizzoni, Andrea
Poluzzi, Elisabetta
Pagotto, Uberto
Di Dalmazi, Guido
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
title The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
title_full The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
title_fullStr The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
title_full_unstemmed The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
title_short The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
title_sort changing face of drug-induced adrenal insufficiency in the food and drug administration adverse event reporting system
topic Online Only Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9282361/
https://www.ncbi.nlm.nih.gov/pubmed/35704533
http://dx.doi.org/10.1210/clinem/dgac359
work_keys_str_mv AT raschiemanuel thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT fusarolimichele thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT massarifrancesco thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT mollicaveronica thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT repaciandrea thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT ardizzoniandrea thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT poluzzielisabetta thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT pagottouberto thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT didalmaziguido thechangingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT raschiemanuel changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT fusarolimichele changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT massarifrancesco changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT mollicaveronica changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT repaciandrea changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT ardizzoniandrea changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT poluzzielisabetta changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT pagottouberto changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem
AT didalmaziguido changingfaceofdruginducedadrenalinsufficiencyinthefoodanddrugadministrationadverseeventreportingsystem